Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 2
Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024
Experts discuss real-world outcomes of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), including data highlights from the CIMBTR registry and insights from a Matching-Adjusted Indirect Comparison (MAIC) of liso-cel vs axicabtagene ciloleucel (axi-cel) in the second-line setting, examining how these findings influence chimeric antigen receptor T-cell therapy (CAR T) selection and decision-making based on patient factors and disease characteristics.
Video Player is loading.
Video content above is prompted by the following:
- At ASH last year, there was an oral presentation looking at real-world outcomes of liso-cel as second-line therapy for R/R LBCL from the CIMBTR registry. What were some data highlights, and how do real-world outcomes influence your day-to-day decision-making?
- What patient factors and/or disease characteristics do you consider when selecting between axi-cel vs liso-cel in the second-line setting? There was updated following from a MAIC of liso-cel vs axi-cel in the second line for R/R LBCL from ASH 2024. Has this data influenced your CAR T selection?
Related Content:
